STIM1 and breast neoplasm: Therefore, these data suggest that the combination of a drug inducing ERα degradation (i.e., LMX) with a drug blocking ERα transcriptional activities and functions (i.e., Tam) in LumA IDC could be an effective approach to treat this kind of breast tumor.